Read + Share
Amedeo Smart
Independent Medical Education
Nakamura Y, Ishizuki S, Iwasaki R, Okiyama N, et al. Remarkable elevation of fibrinolysis markers and procalcitonin associated with dabrafenib plus trametinib combination therapy: Uncommon adverse events. J Dermatol 2020;47:e43-e44.PMID: 31762081
Email
LinkedIn
Facebook
Twitter
Privacy Policy